Posted by Michael Wonder on 17 May 2024
HLB shares plummet following FDA rejection of liver cancer drug approval
17 May 2024 - HLB revealed that its US subsidiary, Elevar Therapeutics, and their Chinese partner, Jiangsu Hengrui Pharmaceuticals, received a complete response letter from the US FDA regarding its hepatocellular carcinoma combination treatment candidate of rivoceranib and camrelizumab.
The complete response letter highlighted two main issues.
